5 Key Takeaways

• 1

  The ABYSS trial involved 3,698 patients with a history of myocardial infarction, comparing beta-blocker interruption to continuation.

• 2

  The primary outcome showed 23.8% of the interruption group experienced adverse cardiovascular events versus 21.1% in the continuation group.

• 3

  The trial did not meet the noninferiority criterion, as the upper boundary of the confidence interval exceeded the predefined margin.

• 4

  Beta-blocker interruption led to significant increases in blood pressure and heart rate compared to those who continued treatment.

• 5

  Quality of life did not improve with beta-blocker interruption, as measured by the European Quality of Life–5 Dimensions questionnaire.